21.25
price down icon14.23%   -3.525
after-market Handel nachbörslich: 21.55 0.30 +1.41%
loading

Lyell Immunopharma Inc Aktie (LYEL) Neueste Nachrichten

pulisher
04:58 AM

Lyell Immunopharma: Q4 Earnings Snapshot - theheraldreview.com

04:58 AM
pulisher
Mar 12, 2026

Lyell Immunopharma 2025 Annual Report: Advancing Next-Generation CAR T-Cell Therapies for Cancer Treatment - Minichart

Mar 12, 2026
pulisher
Mar 12, 2026

Lyell Immunopharma 2025 Financial Results: Annual Loss of $274.4MNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform

Mar 12, 2026
pulisher
Mar 12, 2026

Lyell Immunopharma: Fourth Quarter Financial Results Overview - Bitget

Mar 12, 2026
pulisher
Mar 12, 2026

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results - The Manila Times

Mar 12, 2026
pulisher
Mar 10, 2026

LYEL: Pivotal CAR T-cell trials show strong efficacy, with key data updates and solid funding ahead - TradingView

Mar 10, 2026
pulisher
Mar 09, 2026

Lyell Immunopharma Appoints Smital Shah as Chief Financial and Business Officer Effective March 2026 - Minichart

Mar 09, 2026
pulisher
Mar 09, 2026

Lyell Immunopharma (NASDAQ:LYEL) Shares Gap UpShould You Buy? - MarketBeat

Mar 09, 2026
pulisher
Mar 09, 2026

Lyell Immunopharma (NASDAQ:LYEL) Now Covered by Citizens Jmp - MarketBeat

Mar 09, 2026
pulisher
Mar 09, 2026

Lyell Immunopharma closes $50M equity tranche, names new CFO - Investing.com Nigeria

Mar 09, 2026
pulisher
Mar 09, 2026

Lyell Immunopharma closes $50M equity tranche, names new CFO By Investing.com - Investing.com Canada

Mar 09, 2026
pulisher
Mar 09, 2026

Lyell Immunopharma, Inc. Appoints Smital Shah as Chief Business Officer and Principal Financial Officer, Effective March 9, 2026 - marketscreener.com

Mar 09, 2026
pulisher
Mar 09, 2026

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer - Stock Titan

Mar 09, 2026
pulisher
Mar 09, 2026

Citizens initiates Lyell Immunopharma stock at outperform, $34 target - Investing.com South Africa

Mar 09, 2026
pulisher
Mar 09, 2026

Citizens initiates Lyell Immunopharma stock at outperform, $34 target By Investing.com - Investing.com UK

Mar 09, 2026
pulisher
Mar 09, 2026

Citizens Initiates Coverage on LYEL with Market Outperform Ratin - GuruFocus

Mar 09, 2026
pulisher
Mar 08, 2026

HC Wainwright & Co. Maintains Lyell Immunopharma (LYEL) Neutral Recommendation - MSN

Mar 08, 2026
pulisher
Mar 07, 2026

Take Profit: Will Lyell Immunopharma Inc benefit from rate cutsTrade Volume Summary & Accurate Intraday Trading Signals - baoquankhu1.vn

Mar 07, 2026
pulisher
Mar 07, 2026

Fund Flows: Is Lyell Immunopharma Inc impacted by rising ratesIndex Update & Precise Swing Trade Entry Alerts - baoquankhu1.vn

Mar 07, 2026
pulisher
Mar 07, 2026

Breakouts Watch: Is Lyell Immunopharma Inc stock trending bullishJuly 2025 Weekly Recap & Long-Term Capital Growth Ideas - baoquankhu1.vn

Mar 07, 2026
pulisher
Mar 06, 2026

Lyell Immunopharma Inc expected to post a loss of $2.37 a shareEarnings Preview - TradingView

Mar 06, 2026
pulisher
Mar 03, 2026

Lyell Immunopharma (LYEL) to Release Earnings on Tuesday - Defense World

Mar 03, 2026
pulisher
Feb 27, 2026

Lyell Immunopharma Advances GCC19CART Trial in Metastatic Colorectal Cancer: What Investors Should Know - TipRanks

Feb 27, 2026
pulisher
Feb 26, 2026

LYEL.O Technical Analysis & Stock Price Forecast - Intellectia AI

Feb 26, 2026
pulisher
Feb 25, 2026

LYEL Technical Analysis & ETF Price Forecast - Intellectia AI

Feb 25, 2026
pulisher
Feb 23, 2026

Lyell Immunopharma Announces Participation in March Investor Conferences - GlobeNewswire

Feb 23, 2026
pulisher
Feb 21, 2026

What is the long term forecast for Lyell Immunopharma Inc. stockEarnings Recap Report & Risk Managed Investment Strategies - mfd.ru

Feb 21, 2026
pulisher
Feb 20, 2026

How Lyell Immunopharma Inc. stock reacts to global recession fearsPortfolio Risk Report & Weekly Return Optimization Plans - mfd.ru

Feb 20, 2026
pulisher
Feb 20, 2026

What’s the MACD signal for Lyell Immunopharma Inc.Portfolio Value Summary & Free Verified High Yield Trade Plans - mfd.ru

Feb 20, 2026
pulisher
Feb 20, 2026

Is Lyell Immunopharma Inc. stock gaining market shareWeekly Trend Recap & Stock Market Timing Techniques - mfd.ru

Feb 20, 2026
pulisher
Feb 20, 2026

Can Lyell Immunopharma Inc. stock beat market expectations this quarterJuly 2025 Movers & Reliable Intraday Trade Alerts - mfd.ru

Feb 20, 2026
pulisher
Feb 20, 2026

Will Lyell Immunopharma Inc. stock deliver shareholder valueMarket Trend Review & Fast Gaining Stock Strategy Reports - mfd.ru

Feb 20, 2026
pulisher
Feb 18, 2026

Lyell Immunopharma (NASDAQ:LYEL) Shares Gap DownHere's Why - MarketBeat

Feb 18, 2026
pulisher
Feb 16, 2026

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Up 28.0% in January - MarketBeat

Feb 16, 2026
pulisher
Feb 15, 2026

Can Lyell Immunopharma Inc. maintain sales growthJuly 2025 Outlook & Fast Moving Stock Trade Plans - mfd.ru

Feb 15, 2026
pulisher
Feb 14, 2026

Institution Moves: Can Lyell Immunopharma Inc maintain sales growth2025 Retail Activity & Short-Term Trading Opportunity Alerts - baoquankhu1.vn

Feb 14, 2026
pulisher
Feb 14, 2026

LYEL Should I Buy - Intellectia AI

Feb 14, 2026
pulisher
Feb 13, 2026

Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs - BioPharma Dive

Feb 13, 2026
pulisher
Feb 12, 2026

Lyell Immunopharma (NASDAQ:LYEL) COO Stephen Hill Sells 1,236 Shares - MarketBeat

Feb 12, 2026
pulisher
Feb 12, 2026

Lyell Immunopharma (NASDAQ:LYEL) Insider Sells $39,084.69 in Stock - MarketBeat

Feb 12, 2026
pulisher
Feb 12, 2026

Insider Selling: Lyell Immunopharma (NASDAQ:LYEL) CEO Sells 7,455 Shares of Stock - MarketBeat

Feb 12, 2026
pulisher
Feb 12, 2026

Lyell Immunopharma (NASDAQ:LYEL) Trading Up 7.3%Should You Buy? - MarketBeat

Feb 12, 2026
pulisher
Feb 12, 2026

Lyell Immunopharma Announces Initiation Of Patient Dosing In First-Of-Its-Kind Phase 3 Car T-Cell Clinical Trial - TradingView

Feb 12, 2026
pulisher
Feb 12, 2026

Lyell Immunopharma, Inc. (Lyell) announced that dosing has begun for patients with aggressive large B-cell lymphoma in a groundbreaking Phase 3 clinical trial. - Bitget

Feb 12, 2026
pulisher
Feb 12, 2026

Inside the first head-to-head CAR T cancer trial testing Lyell’s ronde-cel - Stock Titan

Feb 12, 2026
pulisher
Feb 12, 2026

Sentiment Review: Is Lyell Immunopharma Inc. stock gaining market shareJuly 2025 Selloffs & Smart Allocation Stock Reports - mfd.ru

Feb 12, 2026
pulisher
Feb 11, 2026

Insider Selling: Lyell Immunopharma (NASDAQ:LYEL) CEO Sells 438 Shares of Stock - MarketBeat

Feb 11, 2026
pulisher
Feb 11, 2026

Is Lyell Immunopharma Inc. stock trending bullishBreakout Watch & Daily Profit Maximizing Tips - mfd.ru

Feb 11, 2026
pulisher
Feb 10, 2026

Lyell Immunopharma (LYEL) grants CSO 50,000 options, small share sale - Stock Titan

Feb 10, 2026
pulisher
Feb 08, 2026

Pullback Watch: Is Lyell Immunopharma Inc stock trending bullishJuly 2025 Setups & Daily Profit Focused Screening - baoquankhu1.vn

Feb 08, 2026
pulisher
Feb 02, 2026

How do insiders feel about American Express CompanyIPO Watch & Technical Analysis for Trade Confirmation - baoquankhu1.vn

Feb 02, 2026
pulisher
Jan 31, 2026

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Significant Growth in Short Interest - MarketBeat

Jan 31, 2026
pulisher
Jan 22, 2026

Lyell Immunopharma (NASDAQ:LYEL) Trading 13.4% HigherWhat's Next? - MarketBeat

Jan 22, 2026
pulisher
Jan 22, 2026

Earnings Beat: How volatile is Lyell Immunopharma Inc stock2025 Technical Patterns & Smart Allocation Stock Tips - baoquankhu1.vn

Jan 22, 2026
pulisher
Jan 19, 2026

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update - Defense World

Jan 19, 2026
$45.65
price down icon 0.48%
$28.06
price down icon 1.72%
$52.56
price down icon 1.55%
$91.19
price up icon 1.21%
$139.50
price down icon 0.01%
biotechnology ONC
$284.05
price down icon 0.44%
Kapitalisierung:     |  Volumen (24h):